Xvivo Perfusion AB (STU:3XV) ROCE % : 3.67% (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Xvivo Perfusion AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Xvivo Perfusion AB's annualized ROCE % for the quarter that ended in Mar. 2024 was 3.67%.

Xvivo Perfusion AB ROCE % Historical Data

The historical data trend for Xvivo Perfusion AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xvivo Perfusion AB ROCE % Chart

Xvivo Perfusion AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

0.98

-6.93

0.55

1.46

5.19

Xvivo Perfusion AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															2.77	0.91	1.12	14.92	3.67

Xvivo Perfusion AB ROCE % Calculation

Xvivo Perfusion AB's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	8.556	/	( ( (157.644 - 12.27)	+	(196.281 - 12.023) )	/ 2 )
	=	8.556	/	( (145.374	+	184.258)	/ 2 )
	=	8.556	/	164.816
	=	5.19 %

Xvivo Perfusion AB's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	6.712	/	( ( (196.281 - 12.023)	+	(199.148 - 17.655) )	/ 2 )
	=	6.712	/	( ( 184.258	+	181.493 )	/ 2 )
	=	6.712	/	182.8755
	=	3.67 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Xvivo Perfusion AB (STU:3XV) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Xvivo Perfusion AB ROCE % Related Terms

Thank you for viewing the detailed overview of Xvivo Perfusion AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Xvivo Perfusion AB (STU:3XV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xvivo Perfusion AB (STU:3XV) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

XVIPF:USA XVIVO:Sweden 3XV:Germany

Address

Massans gata 10, P.O. Box 53015, Gothenburg, SWE, SE-400 14

Website

https://www.xvivoperfusion.com

Xvivo Perfusion AB is a medical technology company dedicated to extending the life of all major organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments namely, Thoracic: Sales of lung and heart transplant products, Abdominal: Sales of liver and kidney transplant products. Services: Revenue from sales of services in organ recovery (carried out by subsidiary STAR Teams Inc.). The majority of revenue is derived from the Thoracic segment. Geographically, the majority is from the United States.

Xvivo Perfusion AB (STU:3XV) Headlines

No Headlines